FDA Approves AstraZeneca’s IMFINZI Regimen for Bladder Cancer
The FDA approved AstraZeneca’s perioperative IMFINZI plus neoadjuvant enfortumab vedotin-ejfv regimen for eligible adults with muscle-invasive bladder cancer. In VOLGA, it reduced EFS risk by 49% and death risk by 42% versus the comparator.
The FDA approved AstraZeneca’s perioperative IMFINZI plus neoadjuvant enfortumab vedotin-ejfv regimen for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin. In VOLGA, it reduced EFS risk by 49% and death risk by 42% versus the comparator.Material DetailsCon…